[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349202-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349202-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comparison-of-overall-survival-across-treatment-modalities-for-oesophageal-gastroesophageal-and-gastric-cancer-protocol-for-a-systematic-review-and-network-meta-analysis","Comparison of overall survival across treatment modalities for oesophageal, gastroesophageal, and gastric cancer - protocol for a systematic review and network meta-analysis","","Cancers of the oesophagus, gastroesophageal junction (GEJ), and proximal stomach share epidemiological, molecular, and therapeutic features, yet treatment guidelines differ and GEJ tumour classification remains debated. This protocol describes a systematic review and network meta-analysis to synthesize evidence across the disease spectrum. It will compare overall survival between surgery, chemotherapy, chemoradiotherapy, immunotherapy, and multimodal approaches, using risk-of-bias, ranking, and confidence assessment methods.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comparison-of-overall-survival-across-treatment-modalities-for-oesophageal-gastroesophageal-and-gastric-cancer-protocol-for-a-systematic-review-and-network-meta-analysis/349202/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comparison-of-overall-survival-across-treatment-modalities-for-oesophageal-gastroesophageal-and-gastric-cancer-protocol-for-a-systematic-review-and-network-meta-analysis/349202.png","ImageObject",300,407,{"name":42,"@type":43},"Adam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-22","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the primary outcome in the planned review?","Question",{"text":63,"@type":64},"Overall survival, defined as time from diagnosis to death from any cause.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which treatment modalities are included for comparison?",{"text":68,"@type":64},"Surgery, chemotherapy, chemoradiotherapy, immunotherapy, and multimodal approaches.",{"name":70,"@type":61,"acceptedAnswer":71},"How will the study rank and assess confidence in treatment comparisons?",{"text":72,"@type":64},"It will rank interventions using P-scores and assess confidence with CINeMA, reporting results according to PRISMA-NMA.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349202,1790684942,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Aposhttpst:ldioi uoKgio/1ti1t8l/. Ssystem13643‑a0tic26R‑eview03175s‑0 (2026) 15:174 Systematic Reviews  \n PROTOCOL Open Access  \nComparison of overall survival    \nacross treatment modalities for oesophageal, gastroesophageal, and gastric cancer:  \nprotocol for a systematic review and network meta‑analysis  \nFani Apostolidou‑Kiouti1* , Anna Bettina Haidich 1, Dimitris Mavridis2, Aikaterini Ioanna Apostolaki3, DimitrisTsavdaris3 and Adriani Nikolakopoulou 1,4*  \nAbstract  \nBackground Cancers ofthe oesophagus, gastroesophageal junction (GEJ), and proximal stomach share epidemio‑ logical, molecular, and therapeutic characteristics. Despite their similarities, treatment guidelines vary, and the classifi‑ cation of GEJ tumours remains debated. While multiple meta‑analyses have addressed subsets of these malignancies, a comprehensive synthesis comparing all treatment modalities across this disease spectrum is lacking. This study aims to perform a systematic review and network meta‑analysis (NMA) to compare the overall survival outcomes of differ‑ ent treatment modalities, including surgery, chemotherapy, chemoradiotherapy, immunotherapy, and multimodal approaches, in patients with oesophageal, GEJ, and gastric cancers.  \nMethods and analysis We will conduct a systematic literature search in MEDLINE (PubMed) and The Cochrane Library (CENTRAL) without date restrictions. Randomised controlled trials (RCTs) comparing eligible treatments will be included. The primary outcome will be overall survival, defined as time from diagnosis to death from any cause. Secondary outcomes will include progression‑free survival, disease‑specific survival, dropout rates, treatment‑related adverse effects, patterns of relapse, R0 resection rates, surgical morbidity, and mortality. We will look for individual patient data (IPD) from primary studies’ authors and registries. We will assess risk of bias with the Cochrane risk of bias RoB2 tool. We plan to present each pairwise comparison with risk ratios and 95% confidence intervals from random‑ effects meta‑analysis. A random‑effects NMA model will simultaneously compare all treatments in the network. We will rank interventions using P‑scores. In case we manage to access IPD and we believe the transitivity assumption does not hold for a specific comparison (or we have a disconnected network), we will use population adjustment methods to estimate an indirect treatment comparison. We will apply CINeMA to assess confidence in the findingsand we will report results according to PRISMA‑NMA.  \n*Correspondence:  \nFani Apostolidou‑Kiouti[fania@auth.gr](fania@auth.gr)[ ](fania@auth.gr)Adriani Nikolakopoulou  \nadriani. nikolakopoulou@uniklinik‑[freiburg.de](freiburg.de)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nApostolidou‑Kiouti etal. Systematic Reviews (2026) 15:174 Page 2 of 8  \nDiscussion Neoplasms of the oesophagus, the gastroesophageal junction, and the stomach are increasingly being studied together in clinical trials, a trend","cbCaiaumfWupdZRX","https://ap.wps.com/l/cbCaiaumfWupdZRX","pdf",1032571,"English","# Abstract\n## Background\n## Methods and analysis\n## Discussion\n## Systematic review registration\n# Keywords\n# Background","[{\"question\":\"What is the primary outcome in the planned review?\",\"answer\":\"Overall survival, defined as time from diagnosis to death from any cause.\"},{\"question\":\"Which treatment modalities are included for comparison?\",\"answer\":\"Surgery, chemotherapy, chemoradiotherapy, immunotherapy, and multimodal approaches.\"},{\"question\":\"How will the study rank and assess confidence in treatment comparisons?\",\"answer\":\"It will rank interventions using P-scores and assess confidence with CINeMA, reporting results according to PRISMA-NMA.\"}]","Comparison of overall survival across treatment modalities for oesophageal, gastroesophageal, and gastric cancer - protocol for a systematic review and network meta-analysis | PDF",1790082199,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8a105ca5796471f5fdee0b599625bf5.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e77ab8bb3063a3c1e2c7fbf3b943171a.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/352da3b160ebac8f590a90011514b68b.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1acab109460ad1fdbac4fcfc5362dea.webp",980,1301]